SARS-CoV-2 Vaccine Research

and COVID-19 Therapeutic Development

Simple. Powerful. Fast.
Immune System Monitoring with CyTOF

You need answers from every cell in each precious patient sample, and you need them quickly, reliably.

Mass cytometry, powered by CyTOF® technology, can expedite COVID-19 therapeutic and vaccine research studies with best-in-class, highly multiplexed, longitudinal immune monitoring capability.

Faster and more cost-efficient than single-cell RNA-seq, CITE-seq or AbSeq, mass cytometry also provides deeper resolution of immune cell phenotype and function than any flow cytometry or spectral cytometry system.

And CyTOF does it all in a single tube.



Don’t have access to a CyTOF system? No problem! Contact us and we’ll put you in touch with a service provider.

If you have questions, would like a quote or need help finding a service provider, submit the form below to have a Fluidigm representative contact you.

Jump-start your SARS-CoV-2 vaccine and COVID-19 therapeutic research with the Maxpar Direct Immune Profiling System.



Best-in-class longitudinal immune profiling

Solves multi-site study challenges

Panel flexibility and expansion



“We chose the Maxpar Direct Immune Profiling Assay for this study* because it provides a robust and standardized solution for comprehensive immune monitoring that is technically easy to execute and harmonize across multiple study sites.”
—Adeeb Rahman, PhD
Icahn School of Medicine at Mount Sinai

* Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC)

Related Webinars

Seminar: A Complete Immune Monitoring Solution with CyTOF: Ideal for Pandemics and Beyond

De Smet presents early data from the COvid-19 Advanced Genetic and Immunologic Sampling (COntAGIouS) clinical research study (NCT04327570) using the Maxpar® Direct™ Immune Profiling Assay™ and Maxpar Pathsetter™ software.

 

Professor Frederik De Smet, MSc, PhD
Assistant Professor
University of Leuven, Belgium



Profiling of COVID-19 Patient Immune Responses

Ruth Montgomery, PhD, describes her team’s work using mass cytometry in infectious disease studies and how her team will contribute to the IMPACC study by analyzing endotracheal aspirates from participants.

 

Ruth Montgomery, PhD
Professor of Internal Medicine
Director, Yale CyTOF Facility
Associate Dean for Scientific Affairs

Resources

Published research and trials using the Maxpar Direct Immune Profiling Assay

Download a summary of COVID-19 trials and publications using CyTOF.

Publications

National Clinical Trials

  • Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) (NCT04378777)
    Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); 10 participating institutions in North America
  • In-Depth Immunological Investigation of COVID-19. (COntAGIouS) (NCT04327570)
    Sponsor: Universitaire Ziekenhuizen Leuven
  • Antidepressant Trial with P2X7 Antagonist JNJ-54175446 (ATP) (NCT04116606)
    Sponsor: CCTU-Core

Clinical trials using mass cytometry in vaccine research as of September 30, 2020.

Source:clinicaltrials.gov

Clinical Trial Name Sponsor Start Date Phase NCT Number
FluPRINT Study: Characterisation of the Immune and Transcriptional Response to LAIV University of Oxford October 2019 NA* 04222595
CVD 38000: Study of Responses to Vaccination with Typhoid and/or Cholera University of Maryland November 2018 4 03705585
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant Vanderbilt-Ingram Cancer Center/ National Cancer Institute September 2016 2 02860039
Investigating Enteric Fever—Salmonella Typhi and Paratyphi Challenge Study University of Oxford, Oxford Vaccine Group December 2014 NA 02192008
Genetic and Environmental Factors in the Response to Influenza Vaccination (SLVP028) Stanford University October 2014 1 03088904
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection (SLVP030) Stanford University September 2014 1 03453801
CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults University of Maryland October 2013 4 03970304
Study of a New MVA Vaccine for Hepatitis C Virus ReiThera Srl December 2010 1 01296451
Blood Donor CVD 5000 University of Maryland January 2004 4 03971669
Table 1. Clinical trials using mass cytometry to study vaccine response as of September 30, 2020. Source: clinicaltrials.gov * NA=Not applicable

Key Publications Applying Mass Cytometry for Vaccine Research

  1. Brodin, P. “Technologies for assessing vaccine responses in the very young.” Current Opinion in Immunology 65 (2020):28–31.
  2. Chng, M.H.Y. et al. “Large-scale HLA tetramer tracking of T cells during dengue infection reveals broad acute activation and differentiation into two memory cell fates.” Immunity 51 (2019): 1,119–1,135.
  3. Lingblom, C.M.D. et al. “Baseline immune profile by CyTOF® can predict response to an investigational adjuvanted vaccine in elderly adults.” Journal of Translational Medicine 16 (2018): 153.
  4. Lucchesi, S. et al. “From bivariate to multivariate analysis of cytometric data: overview of computational methods and their application in vaccination studies.” Vaccines 8 (2020): 138.
  5. Newell E.W. et al. “Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization.” Nature Biotechnology 31 (2013):623–629.
  6. Palgen, J-L. et al. “Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations.” npj Vaccines (2020): 24.
  7. Palgen, J-L. et al. “NK cell immune responses differ after prime and boost vaccination.” Journal of Leukocyte Biology (2019): 1,055–1,073.
  8. Palgen, J-L. et al. “Prime and boost vaccination elicit a distinct innate myeloid cell immune response.” Scientific Reports 8 (2018): 3,087.
  9. Reeves, P.M. et al. “Application and utility of mass cytometry in vaccine development.” FASEB Journal 32: (2018): 5–15.
  10. Rudolph, M.E. et al. “Diversity of Salmonella Typhi-responsive CD4 and CD8 T cells before and after Ty21a typhoid vaccination in children and adults.” International Immunology (2019): 315–333.
  11. Tomic, A. et al. “SIMON, an automated machine learning system, reveals immune signatures of influenza vaccine responses.” The Journal of Immunology 1203 (2019): 749–759.
  12. Tomic, A. et al. “The FluPRINT dataset, a multidimensional analysis of the influenza vaccine imprint on the immune system.” Scientific Data 6 (2019): 214.
Get more information
For Research Use Only. Not for use in diagnostic procedures.